By Sarah Seton-Rogers
The androgen receptor (AR) antagonist enzalutamide was approved in 2012 by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer (CRPC). Although promising clinical results have been observed with enzalutamide, it is expected that many tumours will develop resistance to this agent. Yang Shen, Charles Sawyers and colleagues have conducted a screen using a combination of in vitro, in vivo and in silico methods to prospectively identify resistance mutations in AR that are selected for during enzalutamide treatment.
